FDA Grants Breakthrough Designation to Rasonque Combo for Pancreatic Cancer
RVMD has more than doubled off its 52-week low of $42.18.
Summary
The FDA granted breakthrough therapy designation to Rasonque (daraxonrasib) in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic adenocarcinoma. This follows the drug's recent approval as a monotherapy for previously treated metastatic PDAC. The designation is based on Phase 1-2 data showing encouraging anti-tumor activity and a manageable safety profile, and it could expedite development and review of the combination regimen. The company has already initiated a Phase 3 trial (RASolute 305) for zoldonrasib, a related asset, but this designation specifically covers the Rasonque combination. The news adds a positive regulatory milestone to the company's pancreatic cancer franchise.
At the time of this announcement, RVMD was trading at $205.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44B. The 52-week trading range was $42.18 to $224.31. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.